New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
12:18 EDTGOOG, GME, BAC, AAPL, LULU, C, AMZN, LDOS, BAXOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday as slides in Citigroup (C) and a number of tech giants weighed on the indexes. The weakness comes in spite of the government's estimate for GDP growth in the fourth quarter having been revised upward, as well as encouraging data about unemployment claims. ECONOMIC EVENTS: The estimate of GDP growth in the fourth guarter was revised up to 2.6% from the prior 2.4% estimate, but analyst had expected it to be bumped up to 2.7% in this third reading. There were 311K initial jobless claims in the week ended March 22, which was below the consensus forecast for 323K claims. Pending home sales fell 0.8% in February from the prior month, missing expectations for them to have risen 0.2%. COMPANY NEWS: Shares of Citigroup dropped 6% after the bank was one of five to have its capital plan rejected by the Federal Reserve. The central bank said Citi's plan reflected a "number of deficiencies" in its planning. Citi was denied its request for a $6.4B share repurchase program and to increase its dividend to 5c per share, but will be permitted to continue with its current capital actions. Following last night's Fed announcment, Citigroup shares were downgraded at Keefe Bruyette and at Bernstein... Shares of Bank of America (BAC) were also lower by nearly 2% near midday, despite receiving approval from the Fed for its 2014 capital plan. The bank will be allowed to repurchase $4B of its common stock and increase its dividend to 5c from 1c per share. The bank also announced a more than $9B settlement with the Federal Housing Finance Agency related to mortgage-backed securities sold to Fannie Mae (FNMA) and Freddie Mac (FMCC) between 2005 and 2007... Shares of Baxter (BAX) rose 5.5% after the company announced plans to split into two separate, independent companies -- one focused on biopharmaceuticals and the other on medical products. The split, which is intended to take the form of a tax-free distribution to Baxter shareholders of a new publicly traded stock in the new biopharmaceuticals company, is expected to be completed by mid-year 2015... Shares of Apple (AAPL), Google (GOOG), Amazon.com (AMZN) and a number of other tech stocks were all lower near noon. MAJOR MOVERS: Among the notable gainers was athletic apparel maker lululemon (LULU), which rose over 6% after the company's fourth quarter results topped analysts' consensus expectation and the company's previously lowered outlook. Also higher was Garmin (GRMN), which gained 4.5% after research firm Oppenheimer joined Citigroup to issue the second positive note about the GPS product maker in two days. Among the noteworthy losers was security, health and engineering solutions firm Leidos (LDOS), which dropped more than 15% after its guidance dissapointed and its COO announced plans to leave the company. Also lower following its earnings reports was video game retailer GameStop (GME), which fell 7%. INDEXES: Near midday, the Dow was down 35.52, or 0.22%, to 16,233.47, the Nasdaq was down 34.23, or 0.82%, to 4,139.35, and the S&P 500 was down 7.94, or 0.43%, to 1,844.62.
News For C;BAC;BAX;LULU;GME;LDOS;AAPL;GOOG;AMZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
June 23, 2015
05:53 EDTLDOSLeidos lost number two executive, says Wells Fargo
Wells Fargo believes Leidos lost its number two executive with Lou Von Thaer resigning to become CEO of privately held DynCorp International. Wells views the loss as unexpected and thinks the news "raises some question as to the stability of the management team" under fairly new CEO Roger Krone. The firm keeps a Market Perform rating on Leidos.
05:51 EDTLDOSLeidos announces resignation of Sector President Lewis Von Thaer
Subscribe for More Information
June 22, 2015
19:36 EDTAAPLApple Music artist royalties may be 'insignificant' during trial, WSJ says
Subscribe for More Information
18:22 EDTGOOGGoogle offers sign-ups to test GoPro virtual reality prototype
Google (GOOG) has created a sign-up page to allow "creators" -- taken to mean video content creators -- to test its "Jump" virtual reality platform. Jump uses 16 GoPro (GPRO) cameras to create virtual reality video "that you can step inside of." Content creators selected by Google will get access to the platform beginning this summer. Reference Link
17:43 EDTAMZNAmazon to pay independent authors by number of pages read, Reuters says
Subscribe for More Information
16:00 EDTAAPL, BACOptions Update; June 22, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 17.45. Option volume leaders: AAPL FB BAC CHK WMB BABA TWTR MU AMBA TSLA JPM
14:42 EDTAAPL, GOOGOculus potential not reflected in Facebook's stock price, Piper Jaffray says
Subscribe for More Information
13:33 EDTAAPLApple iPhone redesign without home button not before 2017, AppleInsider says
Subscribe for More Information
12:12 EDTGOOGUS Supreme Court rejects Google patent appeal over Street View, Reuters says
Subscribe for More Information
09:40 EDTAAPL, BACActive equity options trading on open
Subscribe for More Information
08:09 EDTAAPLMasimo receives CE Mark for MightySat Rx pulse oximeter
Subscribe for More Information
08:02 EDTGOOGTransphorm announces new $70M investment led by KKR
Subscribe for More Information
07:46 EDTAAPLApple CEO: Chinese consumer tastes weighed in product designs, Bloomberg says
Subscribe for More Information
07:31 EDTGOOGFacebook catching up to YouTube in video ads, Reuters says
Facebook (FB) is gaining market share on Google's (GOOG) YouTube in online video advertising, reports Reuters, citing a published Ampere Analysis report. Reference Link
06:32 EDTBAXKamada collaborates with Baxter on clinical trial with Alpha-1 antitrypsin
Kamada (KMDA) reports that the company has entered into a collaboration with Baxalta International, a wholly-owned subsidiary of Baxter (BAX) on a Phase 1/2 clinical trial of Kamada’s proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection. Under the agreement, Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016, with more details on trial design to be provided at a later date. Kamada’s proprietary, highly-purified, liquid form of human AAT has shown positive interim results in a proof-of-concept Phase II study in Graft-versus-Host-Disease conducted at the Fred Hutchinson Cancer Research Center in cooperation with Baxalta. Based on those results, preclinical data published in Blood, and at the American Society of Hematology meeting, and a similar mechanism of action, the companies now plan to expand the AAT indication to the prevention of lung transplant rejection and may use this data to support clinical development worldwide. Baxalta has distribution rights to intravenous AAT for all indications in the U.S., Canada, Australia and New Zealand, while Kamada has rights in all other territories and all other formulations.
06:23 EDTAMZNAmazon updates customer reviews system with machine learning, CNet says
Subscribe for More Information
06:02 EDTLULUStocks with implied volatility below IV index mean; QIHU LULU
Subscribe for More Information
05:59 EDTAAPLApple developing in-house TDDI solutions, DigiTimes reports
Subscribe for More Information
05:55 EDTAAPLApple changes tune over music streaming royalties, Financial Times says
Apple has agreed to pay for all the music carried on its new streaming music service during free trials, reports the Financial Times. The company signaled the climbdown after singer Taylor Sift released an open letter Sunday that denounced Apple Music as "shocking" and "disappointing.", adding that her views were shared by "every artist, writer and producer" in her social circles. The company will now pay for the music it streams during free trials, though it would pay less for each stream than it will when a user has taken a full subscription. Reference Link
June 21, 2015
14:49 EDTGOOGRaven shares may rally in next couple years, Barron's says
The recent selloff in Raven (RAVN) shares "looks like an opportunity," and the company's stock could rally over the next couple years, Barron's contends in its 'Sizing Up Small Caps' column. Barron's notes that the company has partnered with Google (GOOG) to develop high-altitude balloons for the experimental Project Loon, which, if expanded into a full project, could signal a boost for Raven. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use